Coeptis Therapeutics (ZSQR) Stock Price, News & Analysis

Company Overview

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Key Stats

• Today's Range: $12.87 to $14.00
• 50-Day Range: $10.40 to $16.78
• 52-Week Range: $6.80 to $21.41
• Volume: 177,180 shs
• Average Volume: 107,521 shs
• Market Capitalization: $80.74 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Coeptis Therapeutics Stock Analysis - MarketRank™

Coeptis Therapeutics scored higher than 5% of companies evaluated by MarketBeat, and ranked 837th out of 860 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.5 / 5
• Analyst Rating: Sell

Consensus Rating

Coeptis Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Coeptis Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Coeptis Therapeutics is -4.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Coeptis Therapeutics is -4.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Coeptis Therapeutics has a P/B Ratio of 4.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

9.12% of the float of Coeptis Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Coeptis Therapeutics has a short interest ratio ("days to cover") of 9.84.

Change versus previous month

Short interest in Coeptis Therapeutics has recently increased by 14.22%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Coeptis Therapeutics does not currently pay a dividend.

Dividend Growth

Coeptis Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: N/A

News Sentiment

Coeptis Therapeutics has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Coeptis Therapeutics this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Coeptis Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Coeptis Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

24.25% of the stock of Coeptis Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

13.88% of the stock of Coeptis Therapeutics is held by institutions.

ZSQR Stock Analysis - Frequently Asked Questions

How have ZSQR shares performed this year?

Coeptis Therapeutics' stock was trading at $14.25 at the beginning of 2026. Since then, ZSQR shares have decreased by 8.9% and is now trading at $12.98.

How were Coeptis Therapeutics' earnings last quarter?

Coeptis Therapeutics Holdings, Inc. (NASDAQ:ZSQR) issued its earnings results on Thursday, March, 19th. The company reported ($0.12) earnings per share (EPS) for the quarter. The company had revenue of $0.86 million for the quarter. Coeptis Therapeutics had a negative net margin of 803.96% and a negative trailing twelve-month return on equity of 110.89%.

When did Coeptis Therapeutics' stock split?

Shares of Coeptis Therapeutics reverse split on the morning of Tuesday, December 31st 2024.The 1-20 reverse split was announced on Friday, December 27th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, December 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

How do I buy shares of Coeptis Therapeutics?

Shares of ZSQR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Coeptis Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Coeptis Therapeutics investors own include Avino Silver & Gold Mines (ASM), PayPal (PYPL), Tesla (TSLA), Meta Platforms (META), 3M (MMM), PHX Minerals (PHX) and P3 Health Partners (PIII).

Company Calendar

• Last Earnings: 3/19/2026
• Today: 5/07/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ZSQR
• Previous Symbol: NASDAQ:COEP
• CIK: 1759186
• Web: coeptispharma.com
• Phone: 724-934-6467
• Fax: N/A
• Employees: 2
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($2.98)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.92 million
• Net Margins: -803.96%
• Pretax Margin: -900.73%
• Return on Equity: -110.89%
• Return on Assets: -78.30%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 4.16
• Quick Ratio: 4.16

Sales & Book Value

• Annual Sales: $1.36 million
• Price / Sales: 59.36
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.63 per share
• Price / Book: 4.94

Miscellaneous

• Outstanding Shares: 6,220,000
• Free Float: 4,714,000
• Market Cap: $80.74 million
• Optionable: Not Optionable
• Beta: -0.09